Management of hyperkalaemia in chronic kidney disease

Nature Reviews Nephrology

Volumn 10, Issue 11, 2014, Pages 653-662

  Kovesdy, Csaba P ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CATION EXCHANGE RESIN; FLUDROCORTISONE ACETATE; FUROSEMIDE; GLUCONATE CALCIUM; CHELATING AGENT; POTASSIUM;

CHRONIC KIDNEY DISEASE; DIALYSIS; ELECTROCARDIOGRAPHY; HYPERKALEMIA; LONG TERM CARE; POTASSIUM BALANCE; POTASSIUM BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ACUTE DISEASE; BLOOD; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; COMPLICATION; HUMAN; RENAL REPLACEMENT THERAPY;

ACUTE DISEASE; CHELATING AGENTS; CHRONIC DISEASE; ELECTROCARDIOGRAPHY; HUMANS; HYPERKALEMIA; POTASSIUM; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84908248239     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2014.168     Document Type: Review

References (113)

1. Lowrie E. G. & Lew N. L. Death risk in hemodialysis patients. The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am. J. Kidney Dis. 15, 458-482 (1990).
2. Iseki K. et al. Impact o. The initial levels of laboratory variables on survival in chronic dialysis patients. Am. J. Kidney Dis. 28, 541-548 (1996).
3. Hayes J. et al Association of hypo-and hyperkalemia with disease progression and mortality in males with chronic kidney disease. The role of race. Nephron Clin. Pract. 120, c8-c16 2012).
4. Kovesdy C. P. et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2, 999-1007 (2007).
5. Gonick H. C., Kleeman C. R., Rubini M. E. & Maxwell M. H. Functional impairment in chronic renal disease. III. Studies of potassium excretion. Am. J. Med. Sci. 261, 281-290 (1971).
6. Hay es C. P. Jr & Robinson R. R. Fecal potassium excretion in patients on chronic intermittent hemodialysis. Trans. Am. Soc. Artif. Intern. Organs 11, 242-246 (1965).
7. Hayes C. P. Jr, McLeod M. E. & Robinson R. R. An extrarenal mechanism fo. The maintenance of potassium balance in severe chronic renal failure. Trans. Assoc. Am. Physicians 80, 207-216 (1967).
8. Kopple J. D. & Coburn J. W. Metabolic studies of low protein diets in uremia. I. Nitrogen and potassium. Medicine (Baltimore) 52, 583-595 (1973).
9. Schrier R. W. & Regal E. M. Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease. Kidney Int. 1, 156-168 (1972).
10. Bourgoignie J. J., Kaplan M., Pincus J., Gavellas G. & Rabinovitch A. Renal handling of po tassium in dogs with chronic renal insufficiency. Kidney Int. 20, 482-490 (1981).
11. Simmons D. H. & Avedon M. Acid-base alterations and plasma potassium concentration. Am. J. Physiol. 197, 319-326 (1959).
12. Adrogué H. J. & Madias N. E. Changes in plasma potassium concentration during acute acid-base disturbances. Am. J. Med. 71, 456-467 (1981).
13. Grabe r M. A model o. The hyperkalemia produced by metabolic acidosis. Am. J. Kidney Dis. 22, 436-444 (1993).
14. Magner P. O., Robinson L., Halperin R. M., Zettle R. & Halperin M. L. The plasma potassium concentration in metabolic acidosis: a re-evaluation. Am. J. Kidney Dis. 11, 220-224 (1988).
15. Oster J. R., Perez G. O. & Vaamonde C. A. Relationship between blood pH and potassium and phosphorus during acute metabolic acidosis. Am. J. Physiol. 235, F345-F351 (1978).
16. Michael J. M., Dorner I., Bruns D., Ladenson J. H. & Sherman L. A. Potassium load in CPD-pre served whole blood and two types of packed red blood cells. Transfusion 15, 144-149 (1975).
17. Palmer B. F. Managing hyperkalemia caused by inhibitors o. The renin-angiotensin-aldosterone system. N. Engl. J. Med. 351, 585-592 (2004).
18. Heering P. J. et al. Aldosterone resistance in kidney transplantation is in part induced by a down-regulation of mineralocorticoid receptor expression. Clin. Transplant. 18, 186-192 (2004).
19. Laine J. & Holmberg C. Renal and adrenal mechanisms in cyclosporine-induced hyperkalaemia after renal transplantation. Eur. J. Clin. Invest. 25, 670-676 (1995).
20. DeFronzo R. A., Sherwin R. S., Felig P. & Bia M. Nonuremic diabetic hyperkalemia. Possible role of insulin deficiency. Arch. Intern. Med. 137, 842-843 (1977).
21. Glassock R. J., Goldstein D. A., Goldstone R. & Hsueh W. A. Diabetes mellitus, moderate renal insufficiency and hyperkalemia. Am. J. Nephrol. 3, 233-240 (1983).
22. Tuck M. L., Sambhi M. P. & Levin L. Hyporeninemic hypoaldosteronism in diabetes mellitus. Studies o. The autonomic nervous system's control of renin release. Diabetes 28, 237-241 (1979).
23. Arrizabalaga P. et al. Increase in serum potassium caused by ?-2 adrenergic blockade in terminal renal failure: absence of mediation by insulin or aldosterone. Proc. Eur. Dial. Transplant Assoc. 20, 572-576 (198 3).
24. Edes T. E. & Sunderrajan E. V. Heparin-induced hyperkalemia. Arch. Intern. Med. 145, 1070-1072 (1985).
25. Bismuth C. Gaultier M. Conso F. Efthymiou M. L Hyperkalemia in acute digitalis poisoning: prognostic significance and therapeutic implications. Clin. Toxicol. 6 153-162 1973).
26. Bü hler F. R. et al. Antihypertensive ? blocking action as r elated to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am. J. Cardiol. 36, 653-669 (1975).
27. Pedersen E. B. & Kornerup H. J. Relationship between plasma aldosterone concentration and plasma potassium in patients with essential hypertension during alprenolol treatment. Acta Med. Scand. 200, 263-267 (1976).
28. Bakris G. L. et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int. 58, 2084-2092 (2000).
29. Weir M. R. & Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin. J. Am. Soc. Nephrol. 5, 531-548 (2010).
30. Molnar M. Z. et al. Angiotensin-converting enzyme inhibitor and angiotensin receptor blocker use and mortality in patients with chronic kidney disease. J. Am. Coll. Cardiol. 63, 650-658 (2014).
31. Pun P. H., Lehrich R. W., Smith S. R. & Middleton J. P. Predictors of survival after cardiac arrest in outpatient hemodi alysis clinics. Clin. J. Am. Soc. Nephrol. 2, 491-500 (2007).
32. Fleet J. L. et al. Validity o. The International Classification of Diseases 10th revision code for hyperkalaemia in elderly patients at prese ntation to an emergency department and at hospital admission. BMJ Open 2, e002011 (2012).
33. Einhorn L. M. et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch. Intern. Med. 169, 1156-1162 (2009).
34. Drawz P. E., Babineau D. C. & Rahman M. Metabolic complications in elderly adults with chronic kidney disease. J. Am. Geriatr. Soc. 60, 310-315 (2012).
35. Sarafidis P. A. et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin. J. Am. Soc. Nephrol. 7, 1234-1241 (2012).
36. Makani H., Bangalore S., Desouza K. A., Shah A. & Messerli F. H. Efficacy and safety of dual blockade o. The renin-angiotensin system: meta-analysis of randomised trials. BMJ 346, f 360 (2013).
37. Susantitaphong P. et al. Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis. Am. J. Hypertens. 26, 424-441 (2013).
38. Lewis E. J., Hunsicker L. G., Bain R. P. & Rohde R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329, 1456-1462 (1993).
39. Maschio G. et al. Effect o. The angiotensin-converting-enzyme inhibitor benazepril o. The progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 334, 939-945 (1996).
40. [No authors listed] Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk o f terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349, 1857-1863 (1997).
41. Ruggenenti P. et al. Blood-p ressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 365, 939-946 (2005).
42. Mann J. F., Gerstein H. C., Pog ue J., Bosch J. & Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes an. The impact of ramipril. The HOPE randomized trial. Ann. Intern. Med. 134, 629-636 (2001).
43. Weinberg J. M. et al. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch. Intern. Med. 169, 1587-1594 (2009).
44. Iino Y. et al. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension-a report o. The Japanese Losartan Therapy Intended fo. The Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens. Res. 27, 21-30 (2004).
45. Miao Y. et al. Increased serum potassium affects renal outcomes: a post hoc analysis o. The Reduction of Endpoints in NIDDM wit. The Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetol ogia 54, 44-50 (2011).
46. Fried L. F. et al. Combined angiotensin inhibition fo. The treatment of diabetic nephropathy. N. Engl J Med. 369 1892-1903 2013).
47. Sanofi Aventis US. Avapro package insert [online], http://products.sanofi.us/Avapro/Avapro.pdf (2014).
48. Hou F. F. et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med. 354, 131-140 (2006).
49. Bozkurt B., Agoston I. & Knowlton A. A. Complications of inappr opriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J. Am. Coll. Cardiol. 41, 211-214 (2003).
50. Shah K. B., Rao K., Sawyer R. & Gottlieb S. S. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J. Am. Coll. Cardiol. 46, 845-849 (2005).
51. Juurlink D. N. et al. Rates of hyperkalemia after publication o. The Randomized Aldactone Evaluation Study. N. Engl. J. Med. 351, 543-551 (2004).
52. Knoll G. A. et al. Renin-angiotensin system blockade an. The risk of hyperkalemia in chronic hemodialysis patients. Am. J. Med. 112, 110-114 (2002).
53. Ito Y. et al. Long-Term effects of spironolactone in peritoneal dialysis patients. J. Am. Soc. Nephrol. 25, 1094-1102 (2014).
54. Vazquez-Rangel A. et al. Spironolactone to prevent peritoneal fibrosis in peritoneal dialysis patients: a randomized controlled trial. Am. J. Kidney Dis. 63, 1072-1074 (2014).
55. Matsumoto Y. et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J. Am. Coll. Cardiol. 63, 528-536 (2014).
56. Flevar i P. et al. Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients. J. Hypertens. 31, 1239-1244 (2013).
57. Shavit L., Neykin D., Lifschitz M. & Slotki I. Effect of eplerenone on blood pressure an. The renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients-a pilot study. Clin. Nephrol. 76, 388-395 (2011).
58. Vukusich A. et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin. J. Am. Soc. Nephrol. 5, 1380-1387 (2010).
59. Hammer F. et al. Rationale and design o. The Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa). Nephrol. Dial. Transplant. 29, 400-405 (2014).
60. Dittrich K. L. & Walls R. M. Hyperkalemia: ECG manifestations and clinical considerations. J. Emerg. Med. 4, 449-455 (1986).
61. Parham W. A., Mehdirad A. A., Biermann K. M. & Fredman C. S. Hyperkalemia revisited. Tex. Heart Inst. J. 33, 40-47 (2006).
62. Korgaonkar S. et al. Serum potassium and outcomes in CKD: insights fro. The RRI-CKD cohort study. Clin. J. Am. Soc. Nephrol. 5, 762-769 (2010).
63. Pun P. H., Lehrich R. W., Honeycutt E. F., Herzog C. A. & Middleton J. P. Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. Kidney Int. 79, 218-227 (2011).
64. Jadoul M. et al. Modifiable practices associated with sudden death among hemodialysis patients i. The Dialysis Outcomes and Practice Patterns Study. Clin. J. Am. Soc. Nephrol. 7, 765-774 (2012).
65. Xu Q. et al. Serum potassium levels and its variability in incident peritoneal dialysis patients: associations with mortality. PLoS ONE 9, e86750 (2014).
66. Epstein F. H. Signs and symptoms of electrolyte disorders. In Clinical disorders of fluid and electrolyte metabolism (eds Maxwell M. H. & Kleeman C. R.) 499-516 (McGraw-Hill, 1980).
67. Fisch C. Electrolytes an. The heart In The Heart (ed. Hurst J. W.) 1466-1479 McGraw-Hill 1986).
68. Kleeman K. & Singh B. N. Serum electrolytes an. The heart. In Clinical disorders of fluid and electrolyte metabolism (eds Maxwell M. H. & Kleeman C. R.) 145-180 (McGraw-Hill, 1980).
69. Marques J. S. & Diogo A. N. Dead man walking: an extreme case of sinusoidal wave pattern in severe hyperkalemia. J. Am. Coll. Cardiol. 59, 2118 (2012).
70. Petrov D. B. Images in clinical medicine. An electrocardiographic sine wave in hyperkalemia. N. Engl. J. Med. 366, 1824 (2012).
71. Siniorakis E. et al. Hyperkalaemia, pseudohyperkalaemia and electrocardiographic correlates. Int. J. Cardiol. 148, 242-243 (2011).
72. Fordjour K. N., Walton T. & Doran J. J. Management of hyperkalemia in hospitalized patients. Am. J. Med. Sci. 347, 93-100 (2014).
73. Montague B. T., Ouellette J. R. & Buller G. K. Retrospective review o. The frequency of ECG changes in hyperkalemia. Clin. J. Am. Soc. Nephrol. 3, 324-330 (2008).
74. Green D., Green H. D., New D. I. & Kalra P. A. The clinical significance of hyperkalaemia-associated repolarization abnormalities in end-stage renal disease. Nephrol. Dial. T ransplant. 28, 99-105 (2013).
75. Welch A., Maroz N. & Wingo C. S. Hyperkalemia: getting t. The heart o. The matter. Nephrol. Dial. Transplant. 28, 15-16 (2013).
76. Garcia-Palmieri M. R. Reversal of hyperkalemic cardiotoxicity with hypertonic saline. Am. Heart. J. 64, 483-488 (1962).
77. Weisberg L. S. Management of severe hyperkalemia. Crit. Care Med. 36, 3246-3251 (2008).
78. Beeler G. W. Jr & Reuter H. Membrane calcium current in ventricular myocardial fibres. J. Physiol. 207, 191-209 (1970).
79. Chen C. M., Gettes L. S. & Katzung B. G. Effect of lidocaine and quinidine on steady-state characteristics and recovery kinetics of (dV/dt)max in guinea pig ventricular myocardium. Circ. Res. 37, 20-29 (1975).
80. Winkler A. W., Hoff H. E. & Smith P. K. Factors affectin. The toxicity of potassium. Am. J. Physiol. 127, 430-436 (1939).
81. Eliakim M., Rosenberg S. Z. & Braun K. Electrocardiographic changes followin. The administration of hypertonic saline to dogs. Am. Heart J. 58, 97-101 (1959).
82. Kapl an J. L. et al. Hypertonic saline treatment of severe hyperkalemia in nonnephrectomized dogs. Acad. Emerg. Med. 7, 965-973 (2000).
83. Ballantyne F. 3rd, Davis L. D. & Reynolds E. W. Jr. Cellular basis for reversal of hyperkalemic electrocardiographic changes by sodium. Am. J. Physiol. 229, 935-940 (1975).
84. Lens X. M., Montoliu J., Cases A., Campistol J. M. & Revert L. Treatment of hyperkalaemia in renal failure: salbutamol v. insulin. Nephrol. Dial. Transplant 4, 228-232 (1989).
85. Alvestrand A., Wahren J., Smith D. & DeFronzo R. A. Insulin-mediated potassium uptake is normal in uremic and healthy subjects. Am. J. Physiol. 246, E174-E180 (1984).
86. S chwarz K. C., Cohen B. D., Lubash G. D. & Rubin A. L. Severe acidosis and hyperpotassemia treated with sodium bicarbonate infusion. Circulation 19, 215-220 (1959).
87. Allon M. & Shanklin N. Effect of bicarbonate administration on plasma potassium in dialysis patients: interactions with insulin and albuterol. Am. J. Kidney Dis. 28, 508-514 (1996).
88. Mahoney B. A. et al. Emer gency interventions for hyperkalaemia. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD003235. http://dx.doi.org/10.1002/14651858.CD003235.pub2.
89. Scherr L. Ogden D. A. Mead A. W. Spritz N. Rubin A. L Management of hyperkalemia with a cation-exchange resin. N. Engl. J. Med. 264 115-119 1961).
90. Flinn R. B., Merrill J. P. & Welzant W. R. Treatment o. The oliguric patient with a new sodium-exchange resin and sorbitol; a preliminary report. N. Engl. J. Med. 264, 111-115 (1961).
91. Emmett M. et al. Effect of three laxatives and a cation exchange resin on fecal sodium and potassium excretion. Gastroenterology 108, 752-760 (1995).
92. Kamel K. S. & Wei C. Cont roversial issues i. The treatment of hyperkalaemia. Nephrol. Dial. Transplant. 18, 2215-2218 (2003).
93. Kamel K. S. & Schreiber M. Askin. The question again: are cation exchange resins effective fo. The treatment of hyperkalemia? Nephrol. Dial. Transplant. 27, 4294-4297 (2012).
94. Sterns R. H., Rojas M., Bernstein P. & Chennupati S. Ion-exchange resins fo. The treatment of hyperkalemia: are they safe and effective? J. Am. Soc. Nephrol. 21, 733-735 (2010).
95. Gruy-Kapral C. et al. Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease. J. Am. Soc. Nephrol. 9, 1924-1930 (1998).
96. Kayexalate (sodium polystyrene sulfonate, USP cation-exchange resin) FDA Drug Label [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/011287s021lbl.pdf (2009).
97. Chelcun J. L., Sable R. A. & Friedman K. Colonic ulceration in a patient with renal disease and hyperkalemia. JAAPA 25, 34, 37-38 (2012).
98. Gorospe E. C., Lewis J. T. & Bruining D. H. Kayexalate-induced esophageal ulcer in a patient with gastroparesis. Clin. Gastroenterol. Hepatol. 10, A28 (2012).
99. Joo M., Bae W. K., Kim N. H. & Han S. R. Colonic mucosal necrosis following administration of calcium polystryrene sulfonate (Kalimate) in a uremic patient. J. Korean Med. Sci. 24, 1207-1211 (2009).
100. Takeuchi N. et al. Development of colonic perforation during calcium polystyrene sulfonate administration: a case report. Case Rep. Med. 2013, 102614 (2013).
101. Harel Z. et al. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am. J. Med. 126, 264.e9-264.e24 (2013).
102. Gerstman B. B., Kirkman R. & Platt R. Intestinal necrosi s associated with postoperative orally administered sodium polystyrene sulfonate in sorbitol. Am. J. Kidney Dis. 20, 159-161 (1992).
103. Watson M. A. et al. Association of prescription of oral sodium polyst yrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study. Am. J. Kidney Dis. 60, 409-416 (2012).
104. Lillemoe K. D. et al. Intestinal necrosis due to sodium polystyrene (Kayexalate) in sorbitol enemas: clinical and experimental support fo. The hypothesis. Surgery 101, 267-272 (1987).
105. US Food and Drug Administration. Kayexalate (sodium polystyrene sulfonate) powder. Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER) [online], http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm186 845.htm (2009).
106. Watson M., Abbott K. C. & Yuan C. M. Damned if you do, damned if you don't: potassium binding resins in hyperkalemia. Clin. J. Am. Soc. Nephrol. 5, 1723-1726 (2010).
107. DeFronzo R. A. Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int. 17, 118-134 (1980).
108. Pitt B. et al. Safety and tolerability o. The novel non-steroida l mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur. Heart J. 34, 2453-2463 (2013).
109. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01807221 (2014).
110. Chernin G. et al Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardia c and kidney patients on renin-angiotensin-aldosterone system inhibition therapy. Clin. Cardiol. 35 32-36 2012).
111. Pitt B. et al. Evaluation o. The efficacy and safety of RLY5016, a polymeric pot assium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur. Heart J. 32, 820-828 (2011).
112. Buysse J. M., Huang I. Z. & Pitt B. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Future Cardiol. 8, 17-28 (2012).
113. Yang A., Leon A., Nuttall M., Low J. J., Rasmussen H. S. In vitro ion exchange capacity and selectivity of ZS-9, a novel, selective cation trap fo. The treatment of hyperkalemia. Am. J. Kidney Dis. 63, B115 (2014).